Form 4: Belite Bio CFO Sells Shares Under 10b5-1 Plan

Belite Bio's Chief Financial Officer, Hao-Yuan Chuang, has sold a significant number of American depositary shares under a pre-arranged trading plan.

Summary

• Hao-Yuan Chuang, Chief Financial Officer and Director of Belite Bio, Inc. (BLTE), reported the sale of American depositary shares (ADS) on April 9, 2026.
• The transactions were executed under a Rule 10b5-1 trading plan adopted on December 22, 2025.
• A total of 6,100 ADS were sold across multiple transactions at weighted average prices ranging from $180.00 to $183.21.
• Following these sales, Mr. Chuang beneficially owns 93,800 ADS.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as neutral to slightly negative due to the insider selling, despite the use of a 10b5-1 plan, which limits the immediate negative interpretation.

Negatives

• The CFO sold a total of 6,100 shares, indicating a reduction in direct beneficial ownership.

Future Outlook

No specific future outlook or guidance is provided in this filing, as it solely reports on past transactions.

Management Comments

• The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/22/2025.
• The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.

Industry Context

StockSavvy.ai notes that insider sales, even under a 10b5-1 plan, can sometimes be interpreted by the market as a signal of reduced confidence, although the pre-arranged nature of these sales aims to mitigate this perception.

Stakeholder Impact

• Shareholders may view the sale of shares by a key executive with caution, although the 10b5-1 plan provides a structured and pre-determined framework for the sales.

Key Dates

Keywords

Belite Bio, BLTE, Form 4, Insider Trading, Rule 10b5-1, Stock Sale, CFO, ADS